Story perspectives

New Treatments Show Promise for Alopecia Areata Patients

9/6/2025

Summary

Story summary

Ritlecitinib (Litfulo) shows potential for treating alopecia areata by reshaping immune responses and promoting hair growth.
The study identified biomarkers that may predict treatment success in patchy alopecia areata patients.
Deuruxolitinib (Leqselvi) received FDA approval in 2024, proving safe and effective for moderate to severe cases.
The 8 mg dose of deuruxolitinib demonstrated rapid hair regrowth with good safety.
Genetic testing is necessary before prescribing, potentially delaying treatment by a week.

1 of 1

Story summary

Ritlecitinib (Litfulo) shows potential for treating alopecia areata by reshaping immune responses and promoting hair growth.
The study identified biomarkers that may predict treatment success in patchy alopecia areata patients.
Deuruxolitinib (Leqselvi) received FDA approval in 2024, proving safe and effective for moderate to severe cases.
The 8 mg dose of deuruxolitinib demonstrated rapid hair regrowth with good safety.
Genetic testing is necessary before prescribing, potentially delaying treatment by a week.